drugset / Trial / NCT07549451

Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms

NCT07549451

Phase 2 Not yet recruiting 30 enrolled M.D. Anderson Cancer Center Geron Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if imetelstat can help to control MDS/MPNs.

Timeline

Start
2026-10-08
Primary completion
2027-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Imetelstat Oligonucleotide (other) Intravenous